JP2015532920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532920A5 JP2015532920A5 JP2015532473A JP2015532473A JP2015532920A5 JP 2015532920 A5 JP2015532920 A5 JP 2015532920A5 JP 2015532473 A JP2015532473 A JP 2015532473A JP 2015532473 A JP2015532473 A JP 2015532473A JP 2015532920 A5 JP2015532920 A5 JP 2015532920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- acid
- composition according
- day
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- KCGQQXNJMVJUMW-UHFFFAOYSA-N 1,3-oxazole;piperidine Chemical compound C1=COC=N1.C1CCNCC1 KCGQQXNJMVJUMW-UHFFFAOYSA-N 0.000 claims 7
- 125000005605 benzo group Chemical group 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 150000004665 fatty acids Chemical class 0.000 claims 6
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 5
- 239000005556 hormone Substances 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960001534 risperidone Drugs 0.000 claims 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 3
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical class FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 229940108924 conjugated linoleic acid Drugs 0.000 claims 2
- 229960003162 iloperidone Drugs 0.000 claims 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 2
- 229950010634 ocaperidone Drugs 0.000 claims 2
- 229960001057 paliperidone Drugs 0.000 claims 2
- URXZXNYJPAJJOQ-FPLPWBNLSA-N (Z)-icos-13-enoic acid Chemical compound CCCCCC\C=C/CCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-FPLPWBNLSA-N 0.000 claims 1
- IJBFSOLHRKELLR-BQYQJAHWSA-N (e)-dodec-5-enoic acid Chemical compound CCCCCC\C=C\CCCC(O)=O IJBFSOLHRKELLR-BQYQJAHWSA-N 0.000 claims 1
- ZVXDGKJSUPWREP-BQYQJAHWSA-N (e)-tetradec-7-enoic acid Chemical compound CCCCCC\C=C\CCCCCC(O)=O ZVXDGKJSUPWREP-BQYQJAHWSA-N 0.000 claims 1
- KPGGPQIHJCHVLZ-UHFFFAOYSA-N 15-Docosenoic acid Natural products CCCCCCC=CCCCCCCCCCCCCCC(O)=O KPGGPQIHJCHVLZ-UHFFFAOYSA-N 0.000 claims 1
- KPGGPQIHJCHVLZ-BQYQJAHWSA-N 15-docosenoic acid Chemical compound CCCCCC\C=C\CCCCCCCCCCCCCC(O)=O KPGGPQIHJCHVLZ-BQYQJAHWSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705790P | 2012-09-26 | 2012-09-26 | |
| US61/705,790 | 2012-09-26 | ||
| US201361871662P | 2013-08-29 | 2013-08-29 | |
| US61/871,662 | 2013-08-29 | ||
| PCT/EP2013/070106 WO2014049071A1 (en) | 2012-09-26 | 2013-09-26 | Modulators of androgen synthesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210459A Division JP6734346B2 (ja) | 2012-09-26 | 2018-11-08 | アンドロゲン合成モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532920A JP2015532920A (ja) | 2015-11-16 |
| JP2015532920A5 true JP2015532920A5 (enExample) | 2016-11-17 |
| JP6434410B2 JP6434410B2 (ja) | 2018-12-05 |
Family
ID=49293617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532473A Active JP6434410B2 (ja) | 2012-09-26 | 2013-09-26 | アンドロゲン合成モジュレーター |
| JP2018210459A Active JP6734346B2 (ja) | 2012-09-26 | 2018-11-08 | アンドロゲン合成モジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210459A Active JP6734346B2 (ja) | 2012-09-26 | 2018-11-08 | アンドロゲン合成モジュレーター |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9072743B2 (enExample) |
| EP (1) | EP2900270B1 (enExample) |
| JP (2) | JP6434410B2 (enExample) |
| CN (1) | CN104797271B (enExample) |
| AU (2) | AU2013322612B2 (enExample) |
| BR (1) | BR112015006727B1 (enExample) |
| CA (1) | CA2886132C (enExample) |
| ES (1) | ES2734554T3 (enExample) |
| HK (1) | HK1211868A1 (enExample) |
| IL (2) | IL237892B (enExample) |
| MX (1) | MX367782B (enExample) |
| NZ (1) | NZ706067A (enExample) |
| PL (1) | PL2900270T3 (enExample) |
| WO (1) | WO2014049071A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1211868A1 (en) | 2012-09-26 | 2016-06-03 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| US9375433B2 (en) | 2012-09-26 | 2016-06-28 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| CA2950800C (en) * | 2014-05-09 | 2023-01-10 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| SG11201906735RA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| JP2020516283A (ja) * | 2017-04-11 | 2020-06-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ |
| KR20240125690A (ko) | 2017-10-11 | 2024-08-19 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
| CN112020556A (zh) | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| WO1991002527A1 (en) * | 1989-08-21 | 1991-03-07 | Beth Israel Hospital Association | Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6319950B1 (en) | 1997-02-18 | 2001-11-20 | Michael C. Seidel | Suppression of carcinoma using high purity conjugated linoleic acid (CLA) |
| JPH1192343A (ja) * | 1997-09-22 | 1999-04-06 | Shiseido Co Ltd | 毛髪成長期延長剤 |
| JPH11209279A (ja) * | 1998-01-05 | 1999-08-03 | Natural Ltd As | 体重減少および肥満処置の方法 |
| IL139975A0 (en) | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| US6977271B1 (en) * | 2001-08-30 | 2005-12-20 | Health Research, Inc. | Method for inhibition of angiogenesis and vasculogenesis |
| ES2186576B1 (es) * | 2001-10-11 | 2004-09-16 | Universitat De Les Illes Balears | Acido 2-hidroxioleico para utilizar como medicamento. |
| MXPA04007752A (es) * | 2002-02-08 | 2005-06-17 | Abbott Lab | Terapia de combinacion para tratamiento de esquizofrenia. |
| EP1626703A2 (en) * | 2003-05-22 | 2006-02-22 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells |
| WO2005066196A1 (en) * | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Amorphous form of finasteride and processes for its preparation |
| CN100548271C (zh) | 2004-01-20 | 2009-10-14 | 阿勒根公司 | 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物 |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| BRPI0611322A2 (pt) * | 2005-05-31 | 2010-08-31 | Orexigen Therapeutics Inc | métodos e composicões para controlar distúrbios psicóticos |
| WO2008034129A2 (en) * | 2006-09-15 | 2008-03-20 | Cornell Research Foundation Inc. | Treatment of cancer or obesity with conjugated linoleic acids |
| US8420624B2 (en) | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
| AR070313A1 (es) * | 2008-01-03 | 2010-03-31 | Gador Sa | Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma |
| WO2009134383A2 (en) * | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
| CN101366705B (zh) * | 2008-09-28 | 2010-09-08 | 浙江大学 | 利培酮透皮吸收贴片 |
| ES2443045T5 (es) | 2009-04-20 | 2021-05-10 | Allergan Inc | Hidrogeles de fibroína de seda y usos de éstos |
| WO2012026663A1 (ko) * | 2010-08-25 | 2012-03-01 | 이화여자대학교 산학협력단 | 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제 |
| ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| WO2014027973A1 (en) * | 2012-08-14 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Paliperidone oral solution |
| US9375433B2 (en) | 2012-09-26 | 2016-06-28 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| HK1211868A1 (en) | 2012-09-26 | 2016-06-03 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| CA2950800C (en) | 2014-05-09 | 2023-01-10 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
-
2013
- 2013-09-26 HK HK16100002.8A patent/HK1211868A1/xx unknown
- 2013-09-26 CN CN201380054623.0A patent/CN104797271B/zh active Active
- 2013-09-26 EP EP13771104.0A patent/EP2900270B1/en active Active
- 2013-09-26 BR BR112015006727-1A patent/BR112015006727B1/pt active IP Right Grant
- 2013-09-26 PL PL13771104T patent/PL2900270T3/pl unknown
- 2013-09-26 JP JP2015532473A patent/JP6434410B2/ja active Active
- 2013-09-26 MX MX2015003899A patent/MX367782B/es active IP Right Grant
- 2013-09-26 CA CA2886132A patent/CA2886132C/en active Active
- 2013-09-26 WO PCT/EP2013/070106 patent/WO2014049071A1/en not_active Ceased
- 2013-09-26 US US14/037,481 patent/US9072743B2/en active Active
- 2013-09-26 AU AU2013322612A patent/AU2013322612B2/en active Active
- 2013-09-26 NZ NZ706067A patent/NZ706067A/en unknown
- 2013-09-26 ES ES13771104T patent/ES2734554T3/es active Active
-
2015
- 2015-03-22 IL IL237892A patent/IL237892B/en active IP Right Grant
- 2015-05-27 US US14/723,225 patent/US9585887B2/en active Active
-
2017
- 2017-02-27 US US15/444,066 patent/US9808462B2/en active Active
- 2017-08-31 AU AU2017221819A patent/AU2017221819B2/en active Active
- 2017-11-02 US US15/802,005 patent/US20180064713A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210459A patent/JP6734346B2/ja active Active
-
2019
- 2019-05-05 IL IL266446A patent/IL266446A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016011949A2 (pt) | Composto, composição farmacêutica, e, uso dos mesmos | |
| MX2015011504A (es) | Inhibidores de ras y sus usos. | |
| NZ607060A (en) | Substituted imidazoquinoline derivatives as kinase inhibitors | |
| JOP20180120A1 (ar) | مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 | |
| TN2012000428A1 (en) | Bisaryl-bonded aryltriazolones and use thereof | |
| WO2015017821A3 (en) | Therapeutically active compounds and their methods of use | |
| SG10201806565SA (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| MX362857B (es) | Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos. | |
| MX2012002876A (es) | Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico. | |
| MX2015000107A (es) | Derivados de azaindol que actuan como inhibidores de fosfoinositida 3-cinasas (pi3k). | |
| PE20151754A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| MY169330A (en) | Method for inhibition of deubiquitinating activity | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12015502723B1 (en) | Novel cyp17 inhibitors/antiandrogens | |
| SG10201900504XA (en) | Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases | |
| WO2011119722A3 (en) | Use of anatabine to treat inflammation and methods of synthesizing anatabine | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| WO2015104292A3 (en) | Compounds for use in treating or preventing cancerous diseases | |
| WO2011025167A3 (ko) | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물 | |
| EA033054B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
| AU2016204294A1 (en) | Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor | |
| CL2009000510A1 (es) | Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados. | |
| IN2012DN00763A (enExample) | ||
| GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases |